Nouveautés en pathologie thyroïdienne: classification OMS 2022, système Bethesda 2023, biologie moléculaire et testing moléculaire

Mohamed Amine Bani; Sophie Moog; Voichita Suciu; Livia Lamartina; Abir Al Ghuzlan

doi:10.1016/S0007-4551(24)00404-1

Nouveautés en pathologie thyroïdienne: classification OMS 2022, système Bethesda 2023, biologie moléculaire et testing moléculaire

Mohamed Amine Bani, Sophie Moog, Voichita Suciu, Livia Lamartina, Abir Al Ghuzlan

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

Résumé

Advances in Thyroid Pathology: WHO Classification 2022, Bethesda System 2023, molecular biology and molecular testing: Thyroid pathology has experienced significant advances with the publication of the 5th edition of the World Health Organization classification of endocrine tumors in 2022 and the third edition of the Bethesda system for thyroid cytopathology in 2023. At the same time, the availability of next-generation sequencing data coupled with numerous translational research projects have considerably increased our knowledge of the genomics and mechanics of thyroid cancers, enabling us to refine prognosis and propose new targeted therapies. In this review, we will take up the main new features of the WHO 2022 and Bethesda 2023 classifications, as well as molecular biology findings, with an emphasis on the practical implications for clinicians.

Titre traduit de la contribution	Advances in thyroid pathology: WHO Classification 2022, Bethesda System 2023, molecular biology and molecular testing
langue originale	Français
Pages (de - à)	10S5-10S18
journal	Bulletin du Cancer
Volume	111
Numéro de publication	10
Les DOIs	https://doi.org/10.1016/S0007-4551(24)00404-1
état	Publié - 1 oct. 2024

mots-clés

Bethesda system
Thyroid cytopathology
Thyroid pathology
Thyroid tumors
WHO classification

Accès au document

10.1016/S0007-4551(24)00404-1

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{3f0ce141c6ec4997968fe017b04dbcdf,

title = "Nouveaut{\'e}s en pathologie thyro{\"i}dienne: classification OMS 2022, syst{\`e}me Bethesda 2023, biologie mol{\'e}culaire et testing mol{\'e}culaire",

abstract = "Advances in Thyroid Pathology: WHO Classification 2022, Bethesda System 2023, molecular biology and molecular testing: Thyroid pathology has experienced significant advances with the publication of the 5th edition of the World Health Organization classification of endocrine tumors in 2022 and the third edition of the Bethesda system for thyroid cytopathology in 2023. At the same time, the availability of next-generation sequencing data coupled with numerous translational research projects have considerably increased our knowledge of the genomics and mechanics of thyroid cancers, enabling us to refine prognosis and propose new targeted therapies. In this review, we will take up the main new features of the WHO 2022 and Bethesda 2023 classifications, as well as molecular biology findings, with an emphasis on the practical implications for clinicians.",

keywords = "Bethesda system, Thyroid cytopathology, Thyroid pathology, Thyroid tumors, WHO classification",

author = "Bani, {Mohamed Amine} and Sophie Moog and Voichita Suciu and Livia Lamartina and Ghuzlan, {Abir Al}",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Masson SAS. Tous droits r{\'e}serv{\'e}s.",

year = "2024",

month = oct,

day = "1",

doi = "10.1016/S0007-4551(24)00404-1",

language = "Fran{\c c}ais",

volume = "111",

pages = "10S5--10S18",

journal = "Bulletin du Cancer",

issn = "0007-4551",

number = "10",

}

TY - JOUR

T1 - Nouveautés en pathologie thyroïdienne

T2 - classification OMS 2022, système Bethesda 2023, biologie moléculaire et testing moléculaire

AU - Bani, Mohamed Amine

AU - Moog, Sophie

AU - Suciu, Voichita

AU - Lamartina, Livia

AU - Ghuzlan, Abir Al

PY - 2024/10/1

Y1 - 2024/10/1

N2 - Advances in Thyroid Pathology: WHO Classification 2022, Bethesda System 2023, molecular biology and molecular testing: Thyroid pathology has experienced significant advances with the publication of the 5th edition of the World Health Organization classification of endocrine tumors in 2022 and the third edition of the Bethesda system for thyroid cytopathology in 2023. At the same time, the availability of next-generation sequencing data coupled with numerous translational research projects have considerably increased our knowledge of the genomics and mechanics of thyroid cancers, enabling us to refine prognosis and propose new targeted therapies. In this review, we will take up the main new features of the WHO 2022 and Bethesda 2023 classifications, as well as molecular biology findings, with an emphasis on the practical implications for clinicians.

AB - Advances in Thyroid Pathology: WHO Classification 2022, Bethesda System 2023, molecular biology and molecular testing: Thyroid pathology has experienced significant advances with the publication of the 5th edition of the World Health Organization classification of endocrine tumors in 2022 and the third edition of the Bethesda system for thyroid cytopathology in 2023. At the same time, the availability of next-generation sequencing data coupled with numerous translational research projects have considerably increased our knowledge of the genomics and mechanics of thyroid cancers, enabling us to refine prognosis and propose new targeted therapies. In this review, we will take up the main new features of the WHO 2022 and Bethesda 2023 classifications, as well as molecular biology findings, with an emphasis on the practical implications for clinicians.

KW - Bethesda system

KW - Thyroid cytopathology

KW - Thyroid pathology

KW - Thyroid tumors

KW - WHO classification

UR - http://www.scopus.com/inward/record.url?scp=85207939067&partnerID=8YFLogxK

U2 - 10.1016/S0007-4551(24)00404-1

DO - 10.1016/S0007-4551(24)00404-1

M3 - Article

AN - SCOPUS:85207939067

SN - 0007-4551

VL - 111

SP - 10S5-10S18

JO - Bulletin du Cancer

JF - Bulletin du Cancer

IS - 10

ER -